Avalyn Pharma (AVLN) General Counsel named as reporting person in Form 3
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Avalyn Pharma Inc. filed an initial insider ownership report for its General Counsel, Adam H. Golden. The Form 3 lists him as an officer but does not report any share transactions or derivative positions, indicating this filing is purely administrative disclosure of insider status rather than trading activity.
Positive
- None.
Negative
- None.
FAQ
What does Avalyn Pharma Inc.'s Form 3 for AVLN report?
The Form 3 for Avalyn Pharma Inc. identifies Adam H. Golden, the company's General Counsel, as a reporting person. It does not list any share transactions or derivative positions, indicating no insider trades are disclosed in this filing.
Who is the reporting person on Avalyn Pharma's AVLN Form 3?
The reporting person is Adam H. Golden, who serves as General Counsel of Avalyn Pharma Inc. He is reported as an officer and not as a director or ten percent owner in this insider ownership filing.
Does the AVLN Form 3 show any insider buying or selling?
No insider buying or selling is shown. The transaction summary reports zero buy, sell, acquire, dispose, and other transactions, with net buy-sell shares at zero, so the filing reflects status, not trading activity.
Are any derivative securities reported in Avalyn Pharma's Form 3?
No derivative securities are reported. The derivative summary is empty and derivativeTransactionCount is zero, meaning the filing does not disclose options, warrants, or other derivative positions for the reporting person.
Does the AVLN Form 3 indicate significant ownership changes?
The Form 3 does not indicate any ownership changes. It shows no transactions, no exercises, gifts, tax withholdings, or restructurings, so it functions as an initial insider designation rather than a record of changes.